SPARCL1 and gastrointestinal stromal tumor: The SPARCL1 notably decreased the invasion ability of GIST 882 cells by 3.2-fold when compared with vector control cells (P < 0.001), while no statistical significance was observed between the Lv-shNC and normal control group (P > 0.05).